DEFINITIONS OF HISTOCOMPATIBILITY TYING TERMS

Harmonization of Histocompatibility Typing Terms Working Group

Eduardo Nunes1 – AABB
Helen Heslop2 – American Society for Blood and Marrow Transplantation (ASBMT)
Marcelo Fernandez-Vina3, Cynthia Taves3, Dawn R. Wagenknecht3 – American Society for Histocompatibility and Immunogenetics (ASHI)
A. Bradley Eisenbrey4 - College of American Pathologists (CAP)
Gottfried Fischer5, Kay Poulton5 - European Federation for Immunogenetics (EFI),
Kara Wacker6 - Foundation for the Accreditation of Cellular Therapy (FACT)
Carolyn Katovich Hurley7, Harriet Noreen7 - National Marrow Donor Program (NMDP)
Carolyn Katovich Hurley8, Nicoletta Sacchi8 - World Marrow Donor Association (WMDA)

1 AABB, 8101 Glenbrook Road, Bethesda, MD 20814-2749, Phone: +1.301.907.6977, Fax: +1.301.907.6895, E-mail: publicrelations@aabb.org
2 American Society for Blood and Marrow Transplantation (ASBMT), 85 W. Algonquin, Road, Suite 550, Arlington Heights, IL 60005, Phone: (847) 427-0224, Fax: (847) 427-9656, E-mail: mail@asbmt.org
3 ASHI Executive Office, 15000 Commerce Parkway, Suite C, Mt. Laurel, NJ 08054, E-mail: info@ashi-hla.org
4 College of American Pathologists (CAP), 325 Waukegan Road, Northfield, IL 60093-2750, E-mail: media@cap.org
5 European Federation for Immunogenetics (EFI), EFI Central Office c/o Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Bldg 1 E3-Q PO Box 9600, 2300 RC Leiden, The Netherlands, E-mail: sshgeelhoed@lumc.nl
6 Foundation for the Accreditation of Cellular Therapy (FACT), Foundation for the Accreditation of Cellular Therapy, 986065 Nebraska Medical Center, Omaha, NE 68198-6065, E-mail: fact@unmc.edu
7 National Marrow Donor Program (NMDP), 3001 Broadway Street N.E., Suite 100, Minneapolis, MN 55413-17538, E-mail: media@NMDP.org
8 World Marrow Donor Association (WMDA), WMDA Office, Plesmanlaan 1b, 6th floor, 2333 BZ Leiden, The Netherlands, E-mail: wmda@europodonor.nl

Corresponding Author:
Dawn R. Wagenknecht
HLA-Vascular Biology Laboratory
Franciscan St. Francis Health
1600 Albany St.
Beech Grove, IN
Phone: 317-782-7177, FAX: 317-782-6949
Dawn.Wagenknecht@franciscanalliance.org

Key words: HLA typing resolution, HLA matching, verification typing, extended typing.

This article has been published jointly by invitation and consent in both Blood and Human Immunology. Copyright © 2011 American Society of Hematology and American Society for Histocompatibility and Immunogenetics. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Hematology and the American Society for Histocompatibility and Immunogenetics.
Abstract

Histocompatibility testing for stem cell and solid organ transplantation has become increasingly complex as newly discovered HLA alleles are described. HLA typing assignments reported by laboratories are used by physicians and donor registries for matching donors and recipients. To communicate effectively, a common language for histocompatibility terms should be established. In early 2010, representatives from Clinical, Registry and Histocompatibility organizations joined together as the Harmonization of Histocompatibility Typing Terms Working Group to define a consensual language for laboratories, physicians and registries to communicate histocompatibility typing information. The Working Group defined terms for HLA typing resolution, HLA matching and a format for reporting HLA assignments. In addition, definitions of verification typing and extended typing were addressed. The original draft of the Definitions of Histocompatibility Typing Terms was disseminated to colleagues from each organization to gain feedback and create a collaborative document. Commentary gathered during this 90-day review period were discussed and implemented for preparation of this report. Histocompatibility testing continues to evolve thus, the definitions agreed upon today, likely will require refinement and perhaps additional terminology in the future.

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

The definitions below are intended as general concepts. There will be exceptions to these general definitions. These definitions do not imply any specific requirements for HLA typing but are only meant to define useful terms.

Definitions of typing resolution. HLA laboratories should have a written agreement with each entity requesting HLA typing for transplantation regarding the specifications for the resolution of typing. The following terms might be used in the agreement. These definitions do not imply any specific requirements for typing; that decision is made by the HLA typing laboratory in compliance with testing standards and requirements of the test requesting entity.
**Allelic resolution:** The DNA-based typing result is consistent with a single allele as defined in a given version of the WHO HLA Nomenclature Report as described on the reference web site, http://hla.alleles.org. An allele is defined as a unique nucleotide sequence for a gene as defined by the use of all of the digits in a current allele name. Examples include A*01:01:01:01 and A*02:07 (designations based on the IMGT/HLA Database version 3.1.0, July 2010). See Figures 1 and 2 and Table 1.

**High resolution:** A high resolution typing result is defined as a set of alleles that encode the same protein sequence for the region of the HLA molecule called the antigen binding site and that excludes alleles that are not expressed as cell-surface proteins. The antigen binding site includes domain 1 and domain 2 of the class I alpha polypeptides, and domain 1 of the class II alpha and domain 1 of the class II beta polypeptide chains.

**Low resolution:** A DNA-based typing result at the level of the digits comprising the first field in the DNA-based nomenclature. Examples include: A*01; A*02. If the resolution corresponds to a serologic equivalent, this typing result should also be called low resolution.

**Other levels of resolution:** If high resolution can not be obtained or if the laboratory’s agreement with the entity requesting the testing limits the typing efforts to a subset of alleles, the laboratory may report its results at a level of resolution that falls between high resolution and low resolution. Examples are to consider only those alleles expected to be found in the local population or that are designated as common and well-defined (e.g., Cano, P. et al.). A third example is typing that assigns a G group designation (e.g., A*02:01:01G).

**Replacement of the term “confirmatory typing.”** Activities encompassed within the term “confirmatory typing” have become unclear as typing practices and matching criteria have changed over time. It is recommended that the following two terms be used in the place of the words “confirmatory typing” for
better clarity. “Verification typing” and “extended typing” as defined below describe two distinct activities which may be performed separately or concurrently.

**Verification typing:** HLA typing performed on an independent sample (or, for a cord blood unit, from an attached segment or from the unit itself) with the purpose of verifying concordance of that typing assignment with the initial HLA typing assignment. Concordance does not require identical levels of resolution for the two sets of typing but requires the two assignments to be consistent with one another.

**Extended typing:** HLA typing performed to add additional information to an existing HLA assignment. This additional HLA typing may: (1) include assignments at additional HLA loci (e.g., to type HLA-C for an HLA-A,-B,-DRB1 typed volunteer donor) and/or (2) include increased resolution at any previously typed HLA locus e.g., to type an individual with HLA-B serologic assignments to identify the HLA-B alleles. For some cases, extended typing will fulfill requirements for verification typing at a particular locus. In these cases, a combined term “verification/extended typing” might be used.

**Format for reporting HLA assignments.** HLA typing assignments must be clearly understood by the end user. HLA laboratories should have a written agreement with each transplantation entity requesting HLA typing regarding the specifications for the typing. The agreement can include the loci to be tested, the level of resolution of the typing, and the format in which typing results will be reported. The typing assignments must conform with World Health Organization nomenclature for factors of the HLA system (http://hla.alleles.org) and comply with other applicable international conventions (e.g., multiple allele code definitions as designated by the National Marrow Donor Program as described in Bochtler et al.). It might also include the transplant center’s matching requirements if the end user requests that the laboratory evaluate the extent of matching.

**Unresolved alternative assignments:** It is strongly recommended that the report to the end user include all uncertainty in the typing assignment relevant to the level of resolution as stated in the written agreement. This means that genotypes and/or alleles that have not been excluded should be listed in the
report. If it is not possible to provide a list of all unresolved alternatives on the report, the laboratory should indicate that alternative assignments exist and provide a rationale for the HLA assignment that is selected for inclusion in the report. The impact of any uncertainty in HLA assignments for either the potential donor or patient on matching should be addressed in the report.

**Database used in interpretation of typing results:** The version of the IMGT/HLA Database used to interpret the HLA results should be available to the end user upon request.

**Reporting a string of alleles:** Slashes should be used to separate a string of alternative alleles e.g., A*02:01/02:02/02:07/02:20 to mean A*02:01 or A*02:02 or A*02:07 or A*02:20. Based upon resolution requirements, allele names might be truncated from the right, for example A*02:01 is understood to include all silent substitutions, differences outside the coding region and expression codes that begin with the digits 02:01. Left truncation leads to confusion of the allele family and allele number and thus should not be used.

**Matching:** When providing HLA assignments for a potential donor and patient for allogeneic transplantation, the laboratory should include a description of the matching status of the pair as defined by local, national or international standards.

**Directionality of match:** The laboratory may wish to refer to directionality (or vector) of the mismatch in cases where the patient or a potential donor is homozygous at a locus or has a non-expressed allele. If the patient is homozygous and one of the HLA assignments is identical to an assignment of the heterozygous donor (e.g., patient A*01:01:01:01, potential donor A*01:01:01:01, A*23:01), the mismatch may be referred to as a mismatch in the host versus graft vector direction. If the potential donor is homozygous and one of the HLA assignments is identical to an assignment of the heterozygous patient, the mismatch may be referred to as a mismatch in the graft versus host vector direction.

**Matching within a family:**
HLA haplotypes identical by descent: This phrase may be used when (1) parental HLA assignments are available, (2) all four haplotypes are unequivocally defined in the family, (3) the HLA assignments of the parents are clearly distinguishable from one another, and (4) the assignments include HLA class I and class II loci to the extent that potential recombinations have been ruled out. The patient and potential donor who share both haplotypes may be described as HLA identical by descent.

HLA identical for all loci tested: This phrase may be used to refer to matching of related donors who appear to share the HLA loci tested with the patient based on segregation within the family. This phrase would refer to matching in which not all HLA loci are tested (e.g. HLA-A, -B, -C, DRB1 typed but not DQB1 or DPB1) so the possibility of recombination is not excluded.

Families where segregation to confirm identity by descent is not possible: When it is not possible to unequivocally define haplotypes, the phrases used to describe matching should be those used for an unrelated donor as described below.

Matching of patient to unrelated donor or matching within a family where identity by descent can not be ascertained:

Matched for {insert} at {insert} resolution: A phrase like this might be used to refer to the number of loci tested (i.e., two assignments at three loci yielding 6 assignments to include HLA-A,-B,-DRB1 or four loci yielding 8 assignments with the addition of HLA-C or 10 assignments with the addition of HLA-DQB1 or 12 assignments with DPB1), the potential identity of the assignments (e.g., 8/8 or 7/8 or 9/10), and the level of resolution used to determine the potential identity (e.g., high resolution or low resolution). The number of loci to be included in this grading of match should be agreed locally with the service users.

For example, an umbilical cord blood unit may be described as “matched for 6/6 at low resolution for HLA-A and HLA-B and at allelic level resolution for HLA-DRB1” with the patient. For example, an adult volunteer donor may be described as “matched for 9/10 at high resolution” with the patient.
Reference web site: Information on the current status of this document can be found at http://hlalleles.org.

Approval: These definitions have been reviewed by representatives from the following organizations. The extent to which each organization is able to incorporate the definitions above can be found on the web site of each organization.

AABB
American Society for Histocompatibility and Immunogenetics (ASHI)
College of American Pathologists (CAP)
European Federation for Immunogenetics (EFI)
Foundation for the Accreditation of Cellular Therapy (FACT)
National Marrow Donor Program (NMDP)
World Marrow Donor Association (WMDA)
American Society for Blood and Marrow Transplantation (ASBMT)

Authorship Contributions

All authors were members of the Harmonization of Histocompatibility Typing Terms Working Group and as such participated in discussions, writing and editing the definitions of histocompatibility typing terms.

Conflict of Interest

Cynthia Taves is employed by Laboratory Corporation of America Holdings, a commercial company which performs HLA typing, and is Co-Chair of the ASHI Quality and Standards Committee. Harriet Noreen is a Consultant for NMDP. The remaining authors report no conflict of interest.
References


Figure 1. HLA typing resolution. The Venn diagram illustrates increasing levels of HLA typing resolution. The figure on the left shows the antigen binding site of an HLA Class I molecule. High resolution HLA typing defines the specific DNA sequence of the antigen binding site. Allelic resolution defines a single allele as defined by a unique DNA sequence for the HLA gene; in certain instances the allele name may include synonymous DNA substitutions within the coding region, differences in the non-coding region and changes in expression. An example of allelic resolution is A*01:01:01:01 for which synonymous DNA substitutions and differences in the non-coding region have been defined. A*02:07 is also an example of allelic resolution; this allele has not been found to have synonymous DNA substitutions or differences in the non-coding region to date.
Figure 2. Convention for HLA allele naming. The figure illustrates the meaning of each component of an HLA allele name. Fields 3 and 4 may not be used in a name if no synonymous DNA substitutions or differences in a non-coding region are found for a particular allele. For example, based on the IMGT/HLA Database version 3.1.0, July 2010\(^2\), A*02:07 has not been found to have synonymous DNA substitutions or differences in the non-coding region thus fields 3 and 4 have not been assigned for this allele. This figure was kindly provided by Prof Steven Marsh, Anthony Nolan Research Institute, London [hla.alleles.org]'.

© SGE Marsh 04/10
Table 1. Nomenclature of HLA alleles.

<table>
<thead>
<tr>
<th>Nomenclature</th>
<th>Indicates</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA</td>
<td>The HLA region and prefix for an HLA gene.</td>
</tr>
<tr>
<td>HLA-DRB1</td>
<td>A particular HLA locus i.e. DRB1.</td>
</tr>
<tr>
<td>HLA-DRB1*13</td>
<td>A group of alleles which encode the DR13 antigen or sequence homology to other DRB1*13 alleles.</td>
</tr>
<tr>
<td>HLA-DRB1*13:01</td>
<td>A specific HLA allele.</td>
</tr>
<tr>
<td>HLA-DRB1*13:01:02</td>
<td>An allele that differs by a synonymous mutation from DRB1*13:01:01.</td>
</tr>
<tr>
<td>HLA-DRB1*13:01:02</td>
<td>An allele which contains a mutation outside the coding region from DRB1*13:01:01.</td>
</tr>
<tr>
<td>HLA-A*24:09N</td>
<td>A 'Null' allele, an allele which is not expressed.</td>
</tr>
<tr>
<td>HLA-A*30:14L</td>
<td>An allele encoding a protein with significantly reduced or 'Low' cell surface expression.</td>
</tr>
<tr>
<td>HLA-A*24:02:01:02L</td>
<td>An allele encoding a protein with significantly reduced or 'Low' cell surface expression, where the mutation is found outside the coding region.</td>
</tr>
<tr>
<td>HLA-B*44:02:01:02S</td>
<td>An allele encoding a protein which is expressed as a 'Secreted' molecule only.</td>
</tr>
<tr>
<td>HLA-A*32:11Q</td>
<td>An allele which has a mutation that has previously been shown to have a significant effect on cell surface expression, but where this has not been confirmed and its expression remains 'Questionable'.</td>
</tr>
</tbody>
</table>

The table was adapted from one kindly provided by Prof Steven Marsh, Anthony Nolan Research Institute, London [hla.alleles.org].
Definitions of histocompatibility typing terms

Eduardo Nunes, Helen Heslop, Marcelo Fernandez-Vina, Cynthia Taves, Dawn R. Wagenknecht, A. Bradley Eisenbrey, Gottfried Fischer, Kay Poulton, Kara Wacker, Carolyn Katovich Hurley, Harriet Noreen and Nicoletta Sacchi